Tenofovir is a reverse transcriptase inhibitor used for the treatment of HIV/AIDS. A new synthetic route for the preparation of (<i>R</i>)-9-(2-hydroxypropyl)adenine (HPA), which is a key intermediate in the synthesis of Tenofovir has been developed. This route makes use of cost-effective acyclic precursors in the place of an expensive adenine moiety and expensive propylene carbonate. In addition, the use of a more cost effective base, ethyl magnesium bromide, for the alkylation of HPA has improved yields and allowed for easier isolation of intermediates. Isolation of these intermediates lead to the synthesis of Tenofovir, which can be later synthesized into the prodrugs Disoproxil Fumarate (TDF) and Tenofovir Alafenamide Fumarate (TAF). Herein we describe the key improvements towards the synthesis of Tenofovir which include construction of the adenine core from acyclic precursors, use of an inexpensive amino propanol to install chirality, and use of an alternate base for the alkylation of HPA

Key improvements towards the preparation of antiretroviral drug tenofovir

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.